{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Group+2+%28DMARDS+treated+group%29",
    "query": {
      "intervention": "Group 2 (DMARDS treated group)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T21:36:36.395Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02349295",
      "title": "A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriatic Arthritis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ixekizumab 80 mg Q4W",
          "type": "DRUG"
        },
        {
          "name": "Ixekizumab 80 mg Q2W",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 363,
      "start_date": "2014-12-31",
      "completion_date": "2019-06-26",
      "has_results": true,
      "last_update_posted_date": "2020-07-01",
      "last_synced_at": "2026-09-23T21:36:36.395Z",
      "location_count": 59,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02349295"
    },
    {
      "nct_id": "NCT05782335",
      "title": "Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Hospital for Special Surgery, New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2022-11-01",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-09-23T21:36:36.395Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05782335"
    },
    {
      "nct_id": "NCT01717846",
      "title": "Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Apoptotic DNA Damage",
        "Rheumatoid Arthritis",
        "T-cell Lymphocytosis"
      ],
      "interventions": [
        {
          "name": "Group 1 or Orencia treated group",
          "type": "DRUG"
        },
        {
          "name": "Group 2 (DMARDS treated group)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 0,
      "start_date": "2012-12",
      "completion_date": "2014-11",
      "has_results": false,
      "last_update_posted_date": "2016-05-11",
      "last_synced_at": "2026-09-23T21:36:36.395Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01717846"
    },
    {
      "nct_id": "NCT01197534",
      "title": "Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "fostamatinib",
          "type": "DRUG"
        },
        {
          "name": "placebo, fostamatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 913,
      "start_date": "2010-09",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2014-04-17",
      "last_synced_at": "2026-09-23T21:36:36.395Z",
      "location_count": 57,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 54 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01197534"
    },
    {
      "nct_id": "NCT02451748",
      "title": "IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Lab Work",
          "type": "OTHER"
        },
        {
          "name": "Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)",
          "type": "DRUG"
        },
        {
          "name": "Certolizumab pegol (CDP870, tradename Cimzia)",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Sulfasalazine",
          "type": "DRUG"
        },
        {
          "name": "Medrol",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Triamcinolone",
          "type": "DRUG"
        },
        {
          "name": "Naproxen",
          "type": "DRUG"
        },
        {
          "name": "Leflunomide",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "humira",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2015-08",
      "completion_date": "2017-12",
      "has_results": true,
      "last_update_posted_date": "2024-07-10",
      "last_synced_at": "2026-09-23T21:36:36.395Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02451748"
    },
    {
      "nct_id": "NCT05543642",
      "title": "The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatic Diseases"
      ],
      "interventions": [
        {
          "name": "Hepatitis A vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Diphtheria, pertussis, and tetanus booster vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 129,
      "start_date": "2022-10-11",
      "completion_date": "2026-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-09-23T21:36:36.395Z",
      "location_count": 7,
      "location_summary": "Northport, Alabama • Riverview, Florida • Boise, Idaho + 4 more",
      "locations": [
        {
          "city": "Northport",
          "state": "Alabama"
        },
        {
          "city": "Riverview",
          "state": "Florida"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Clovis",
          "state": "New Mexico"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05543642"
    },
    {
      "nct_id": "NCT01307423",
      "title": "Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriatic Arthritis"
      ],
      "interventions": [
        {
          "name": "Apremilast 20mg",
          "type": "DRUG"
        },
        {
          "name": "Apremilast 30mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 529,
      "start_date": "2010-12-09",
      "completion_date": "2017-08-16",
      "has_results": true,
      "last_update_posted_date": "2022-06-14",
      "last_synced_at": "2026-09-23T21:36:36.395Z",
      "location_count": 30,
      "location_summary": "Phoenix, Arizona • Palm Desert, California • Doral, Florida + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01307423"
    }
  ]
}